An Open-label, Multicenter Protocol Providing Pegylated Interferon Alfa-2a (Pegasys) as Monotherapy or in Combination With Ribavirin (Copegus) for Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols
Phase of Trial: Phase III
Latest Information Update: 03 Sep 2013
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Roche
- 16 May 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01853254).
- 02 May 2009 Additional location identified as reported by Roche records.
- 19 Jun 2008 500 patients are expected to be enrolled according to Roche.